EP1830924B1 - Prevention of thrombus formation and/or stabilization - Google Patents
Prevention of thrombus formation and/or stabilization Download PDFInfo
- Publication number
- EP1830924B1 EP1830924B1 EP05820601A EP05820601A EP1830924B1 EP 1830924 B1 EP1830924 B1 EP 1830924B1 EP 05820601 A EP05820601 A EP 05820601A EP 05820601 A EP05820601 A EP 05820601A EP 1830924 B1 EP1830924 B1 EP 1830924B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fxii
- mice
- injury
- platelet
- formation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000007536 Thrombosis Diseases 0.000 title claims description 67
- 230000015572 biosynthetic process Effects 0.000 title claims description 64
- 230000006641 stabilisation Effects 0.000 title claims description 10
- 238000011105 stabilization Methods 0.000 title claims description 10
- 230000002265 prevention Effects 0.000 title description 2
- 108010080865 Factor XII Proteins 0.000 claims description 27
- 102000000429 Factor XII Human genes 0.000 claims description 27
- 230000004913 activation Effects 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 108010071241 Factor XIIa Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 104
- 210000001772 blood platelet Anatomy 0.000 description 83
- 208000027418 Wounds and injury Diseases 0.000 description 48
- 230000006378 damage Effects 0.000 description 48
- 208000014674 injury Diseases 0.000 description 48
- 229920001436 collagen Polymers 0.000 description 31
- 102000008186 Collagen Human genes 0.000 description 30
- 108010035532 Collagen Proteins 0.000 description 30
- 230000015271 coagulation Effects 0.000 description 28
- 238000005345 coagulation Methods 0.000 description 28
- 210000002381 plasma Anatomy 0.000 description 23
- 230000002950 deficient Effects 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 20
- 208000032843 Hemorrhage Diseases 0.000 description 19
- 208000034158 bleeding Diseases 0.000 description 19
- 230000000740 bleeding effect Effects 0.000 description 19
- 230000035602 clotting Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 108090000190 Thrombin Proteins 0.000 description 17
- 229960004072 thrombin Drugs 0.000 description 17
- 230000007812 deficiency Effects 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 108010000499 Thromboplastin Proteins 0.000 description 14
- 102000002262 Thromboplastin Human genes 0.000 description 14
- 206010053567 Coagulopathies Diseases 0.000 description 13
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 13
- 230000007547 defect Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 230000023597 hemostasis Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 102000009123 Fibrin Human genes 0.000 description 11
- 108010073385 Fibrin Proteins 0.000 description 11
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 229950003499 fibrin Drugs 0.000 description 11
- 210000002565 arteriole Anatomy 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 9
- 102100035792 Kininogen-1 Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 230000023555 blood coagulation Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 102000003827 Plasma Kallikrein Human genes 0.000 description 8
- 108090000113 Plasma Kallikrein Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000005995 Aluminium silicate Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 235000012211 aluminium silicate Nutrition 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000006623 intrinsic pathway Effects 0.000 description 7
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000010118 platelet activation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 230000002785 anti-thrombosis Effects 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
- 108010048623 Collagen Receptors Proteins 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 102100038394 Platelet glycoprotein VI Human genes 0.000 description 5
- 101710194982 Platelet glycoprotein VI Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 230000006624 extrinsic pathway Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000003805 procoagulant Substances 0.000 description 5
- 230000002947 procoagulating effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 206010003178 Arterial thrombosis Diseases 0.000 description 4
- 102100023804 Coagulation factor VII Human genes 0.000 description 4
- 108010023321 Factor VII Proteins 0.000 description 4
- 201000007176 Factor XII Deficiency Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 229940012413 factor vii Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- -1 sulfatides Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 206010003162 Arterial injury Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000000507 Integrin alpha2 Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 208000024248 Vascular System injury Diseases 0.000 description 3
- 208000012339 Vascular injury Diseases 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000012771 intravital microscopy Methods 0.000 description 3
- 210000003975 mesenteric artery Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000003331 prothrombotic effect Effects 0.000 description 3
- 230000002885 thrombogenetic effect Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 102000007347 Apyrase Human genes 0.000 description 2
- 108010007730 Apyrase Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 102000009268 Collagen Receptors Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010014513 Embolism arterial Diseases 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 2
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 101150047356 dec-1 gene Proteins 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 102000013373 fibrillar collagen Human genes 0.000 description 2
- 108060002894 fibrillar collagen Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 230000003558 thrombophilic effect Effects 0.000 description 2
- 231100000216 vascular lesion Toxicity 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- 238000010865 video microscopy Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- WPUZGNPQMIWOHE-UHFFFAOYSA-N 3',6'-diacetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid Chemical compound O1C(=O)C2=CC(C(O)=O)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 WPUZGNPQMIWOHE-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005133 Bleeding tendencies Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000011029 Congenital factor XII deficiency Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710194146 Ecotin Proteins 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 108010059382 Zea mays trypsin inhibitor Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 108090001015 cancer procoagulant Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 108010077026 collagen-related peptide Proteins 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940089602 epinephrine injection Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 201000007219 factor XI deficiency Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000012766 histopathologic analysis Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012836 macromolecular constituent Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the subject of the present invention is, in the most general aspect, the prevention of the formation and/or stabilization of three-dimensional arterial or venous thrombi.
- the present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII activity and preventing the formation and/or the stabilization of thrombi and thrombus growth. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
- Vessel wall injury triggers sudden adhesion and aggregation of blood platelets, followed by the activation of the plasma coagulation system and the formation of fibrin-containing thrombi, which occlude the site of injury. These events are crucial to limit posttraumatic blood loss but may also occlude diseased vessels leading to ischemia and infarction of vital organs.
- blood coagulation proceeds by a series of reactions involving the activation of zymogens by limited proteolysis culminating in the fulminant generation of thrombin, which converts plasma fibrinogen to fibrin and potently activates platelets.
- collagen- or fibrin-adherent platelets facilitate thrombin generation by several orders of magnitude by exposing procoagulant phosphatidyl serine (PS) on their outer surface which propagates assembly and activation of coagulation protease complexes and by direct interaction between platelet receptors and coagulation factors.
- PS procoagulant phosphatidyl serine
- extrinsic vessel wall
- intrinsic blood-borne
- TF integral membrane protein tissue factor
- FXII factor XII
- aPTT partial thromboplastin time
- the coagulation cascade can become activated inappropriately and result in the formation of haemostatic plugs inside the blood vessels. Thereby, vessels can become blocked and the blood supply to distal organs limited. This process is known as thromboembolism and is associated with high mortality.
- prosthetic devices that are in contact with blood is severely limited because of activation of the coagulation cascade and coating of the prosthetic surface, often compromising its function. Examples of such prosthetic devices are haemodialysers, cardiopulmonary by-pass circuits, vascular stents and in-dwelling catheters. In cases where such devices are used, anticoagulants, such as heparin, are used to prevent fibrin from depositing on the surface.
- HIT heparin induced thrombocytopenia
- Pixley, R.A. et al. J. Clin. Invest. 91. 61-68 (1993 ) discloses an antifactor XII mAb (mAb C6B7) to block the activation of factor XII and subsequently the activation of the remaining contact system in vivo in a lethal hypotensive bacteremic baboon model. Treatment with this mAb did not affect disseminated intravascular coagulation (DIC).
- Stassen et al Thrombosis & Haemostasis, vol. 74, no. 2, 1995-01-01, pages 655-659 ) describes in vivo anti-thrombotic effects of aprotinin and bovine pancreatic trypsin inhibitors mutants
- the subject of the invention is the use of at least one antibody for inhibiting factor XII and preventing the formation and/or the stabilization of three-dimensional arterial or venous thrombi.
- the anti-FXII antibody respective inhibitor may hereby function so as inhibiting the activation of FXII and/or interfere with other portions of the FXII molecule that are critically involved in FXII activation.
- the present invention further provides the use of such an antibody in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i. e. stroke or myocardial infarction.
- the use of at least one anti-FXII antibody e.g. like F1 antibody (MoAb F1, Ravon et al., Blood. 1995 Dec 1;86(11):4134-43 ) to inhibit FXII-driven thrombus formation is according to the present invention.
- F1 antibody MoAb F1, Ravon et al., Blood. 1995 Dec 1;86(11):4134-43
- a pharmaceutical formulation comprising at least one antibody, which is suitable for inhibiting factor XII and which prevents the formation and/or the stabilization of three-dimensional arterial or venous thrombi.
- the antibody used for the pharmaceutical formulation is an anti-FXII antibody (e.g. like F1 antibody (MoAb F1, Ravon et al., Blood. 1995 Dec 1;86(11):4134-43 )).
- the antibody may also be a fragment of same or mimetic retaining the inhibitory activity, for example analogues of Kunitz Protease Inhibitor domain of amyloid precursor protein as disclosed in US Patent 6,613,890 especially in columns 4 through 8.
- Other suitable inhibitors may be Hamadarin as disclosed by Harahiko Isawa et al. in The Journal of Biological Chemistry, Vol. 277, No. 31 (March 2, pp. 27651 - 27658, 2002 ).
- a suitable Com Trypsin inhibitor and methods of its production are disclosed in Zhi-Yuan Chen et al., Applied and Environmental Microbiology, March 1999, p. 1320 - 1324 and reference 19 cited ibidem.
- FXIIa inhibitors could be designed on the bases of a crystal structure of FXII. Therefore several FXII domains or the light chain could be expressed recombinantly in expression systems such as E. coli, yeast or mammalian cells. Then the protein is purified and crystallized using standard procedures as described for the FXII substrate FXI ( Jin L, et al. (2005) Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions. J Biol Chem.
- small molecule serine protease inhibitors could be included to stabilize the FXII structure.
- Such formulations comprising small molecule inhibitors of protein targets, which can be for example designed guided by crystals of these target proteins, are well known in the art and include pharmaceutical formulations that may be, for example, administered to a patient systemically, such as parenterally, or orally or topically.
- parenteral as used here includes subcutaneous, intravenous, intramuscular, intra-arferial and intra-tracheal injection, instillation, spray application and infusion techniques.
- Parenteral formulations are preferably administered intravenously, either in bolus form or as a constant infusion, or subcutaneously, according to known procedures.
- Preferred liquid carriers which are well known for parenteral use, include sterile water, saline, aqueous dextrose, sugar solutions, ethanol, glycols and oils.
- Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants and wetting agents, etc.
- Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs or the like, or may be presented as a dry product for reconstitution with water or other suitable vehicle for use.
- Such liquid preparations may contain conventional additives, such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.
- Formulations suitable for topical application may be in the form of aqueous or oily suspensions, solutions, emulsions, gels or, preferably, emulsion ointments.
- Formulations useful for spray application may be in the form of a sprayable liquid or a dry powder.
- factor XII as an anti-thrombotic target by inhibiting factor XII by at least one antibody and/or one inhibitor and preventing therefore the formation and/or the stabilization of three-dimensional thrombi in the vessel is provided.
- Factor XII-deficient mice were used to analyze the function of the intrinsic coagulation cascade in hemostasis and thrombosis. Intravital fluorescence microscopy and ultrasonic flow measurements revealed a severe defect in the formation and stabilization of three-dimensional thrombi in different arterial branches of the vascular system. Reconstitution of the mutant mice with human factor XII restored the intrinsic coagulation pathway in vitro and arterial thrombus formation in vivo. Mechanistically, the procoagulant activity of the intrinsic pathway was critically promoted by activated platelets. These results place the FXII-induced intrinsic blood coagulation cascade in a central position in the process of arterial thrombus formation linking plasmatic coagulation with platelet aggregation.
- Figure 1 describes the coagulation analysis of FXII deficient mice:
- B Peripheral blood counts in thousands/ ⁇ l and global coagulation parameters of FXII-/- and wt mice. The abbreviations are white blood counts (WBC), activated partial thromboplastin time (aPTT) and prothrombin time (PT). Values give mean values ⁇ SD of 10 mice of each genotype.
- WBC white blood counts
- aPTT activated partial thromboplastin time
- PT prothrombin time
- C Contact system proteins FXII, plasma kallikrein (PK) and high molecular weight kininogen (HK) probed in 0.3 ⁇ l wt and FXII-/- plasma by Western blotting using specific antibodies. A molecular weight standard is given on the left.
- D Recalcification clotting times were determined in platelet free (upper panel) and platelet rich (lower panel) plasma from C57BU6 and 129sv wt, FXII-/-, FcR ⁇ -/- and integrin ⁇ 2-deficient mice following activation with kaolin (dark columns) or collagen (light columns). The effect of JON/A was analyzed in C57BU6 plasma supplemented with 50 ⁇ g/ml antibody. Means ⁇ STD from 6 experiments are given.
- FIG. 2 Thromboembolic mortality was observed following the intravenous injection of collagen (0.8 mg/kg) and epinephrine (60 ⁇ g/kg). All wild-type mice died within 5 min. Animals that were alive 30 min after challenge were considered survivors.
- C Heparinized platelet rich plasma from wild-type and FXII-/- mice was stimulated with collagen (10 ⁇ g/ml) or ADP (5 ⁇ M) and light transmission was recorded in a standard aggregometer. The results shown are representative of six mice per group.
- Figure 3 describes the defective thrombus formation in mice lacking factor XII in vivo. Thrombus formation in vivo was monitored on mesenteric arterioles upon injury induced with 20% FeCl3.
- A Single platelet adhesion is detected 5 min after injury in all mouse strains, 7 to 8 minutes after injury the first thrombi in wt mice were observed, whereas in FXII-/- the first thrombi occurred 14 to 35 minutes after injury and in FXI-/- 5 to 35 minutes after injury.
- B Thrombus formation was observed in 100% of mesenteric arteries in wild type mice, but only in 50% of FXII-/- mice and in 44.4% of FXI-/- mice.
- C The photomicrographs show representative images 2 min after injury.
- Figure 5 describes the defect in thrombus formation in FXII deficient animals which is restored by human FXII.
- A Thrombus formation upon FeCl 3 induced injury was observed in 100% of mesenteric arteries in wild-type mice as well as in FXII-/- mice injected with human FXII.
- B Formed thrombi occluded the vessel in average 25 minutes after injury in wild-type mice and in 22.7 minutes after injury in FXII-/- mice injected with human FXII. Each symbol represents one individual.
- C Representative pictures are shown.
- Figure 6 describes the anti-FXII antibodies inhibiting thrombus formation in mice in vivo.
- Wild-type mice received 2 mg/kg anti-FXII antibodies or non-immune IgG i.v.. After 15 min, thrombus formation in vivo was monitored on mesenteric arterioles upon injury induced with 20% FeCl 3 .
- A Single platelet adhesion is detected 5 min after injury in both groups. After 7 to 8 minutes the first thrombi mice in control IgG-treated mice were observed, whereas in anti-FXII-treated mice the first thrombi occurred 12 to 32 minutes after injury.
- B Thrombus formation was observed in 100% of mesenteric arteries in control mice, but only in 60% of anti-FXII-treated mice.
- C Time to complete occlusion is shown. Each symbol represents one individual.
- Figure 7 describes a revised model of arterial thrombus formation.
- thrombin formation is predominantly due to tissue factor (TF) exposure in the subendothelial matrix.
- TF tissue factor
- FVII tissue factor
- FII thrombin
- a potential contribution of the intrinsic pathway of coagulation for pathological thrombus formation in vivo was assessed by intravital microscopy- and flow measurement-based models of arterial thrombosis using mice lacking factor XII. While initial adhesion of platelets at sites of injury is not altered in the mutant animals, the subsequent formation and stabilization of three-dimensional thrombi is severely defective. This defect was seen in different branches of the vasculature and could be completely restored by exogenous human factor XII. These findings establish the factor XII-driven intrinsic coagulation pathway as a major link between primary and secondary hemostasis in a revised model of thrombus formation.
- FXII-deficient mice were generated.
- FXII-/- mice are healthy, phenotypically indistinguishable from their wild-type littermates, and fertile.
- Detailed histological and hemostasiological analyses showed no correlates for increased thrombosis or bleeding in FXII-/- mice despite a prolonged aPTT of 68 ⁇ 17 sec and recalcification time of 412 ⁇ 78 sec in retroorbitally collected plasma (wt: 23 ⁇ 4 and 210 ⁇ 31 sec) ( Pauer,H.U., et al. (2004).
- Peripheral blood cell counts of mutant mice did not differ from wild-type controls.
- the prothrombin time (PT) of FXII-/- mice was similar to the wild-type (8.9 ⁇ 1.3 vs.
- Blood coagulation and platelet activation are complementary and mutually dependent processes. Platelets interact with and contribute to the activation of several coagulation factors and the central coagulation product thrombin is a potent platelet activator. Therefore, next the contribution of platelets and FXII was examined to clot formation in more detail. For this, we induced clotting using either kaolin that classically activates FXII but has no direct effect on platelets or collagen, which activates both FXII and platelets where it interacts with numerous receptors, most importantly ⁇ 2 ⁇ 1 integrin and GPVI. In the presence, but not in the absence of platelets, collagen was superior to kaolin for clot formation in wild-type plasma ( Figure 1 D) .
- thrombus formation is frequently initiated by fissuring or abrupt disruption of the atherosclerotic plaque in the arterial branch of the vasculature leading to unphysiologically strong platelet activation and procoagulant activity on the surface on the subendothelial layers.
- FXII Factorin-associated thrombus formation
- thrombus formation was studied in wild-type and FXII-/- mice, employing different models of arterial injury.
- oxidative injury was induced in mesenteric arterioles (60 - 100 ⁇ m in diameter) and thrombus formation was examined by in vivo fluorescence microscopy.
- FeCl 3 ferric chloride
- FeCl 3 -induced arterial thrombus formation is known to depend on platelets and thrombin generation but it is unclear how well this type of injury resembles the thrombogenic milieu produced in diseased vessels, e.g. upon rupture of the atherosclerotic plaque. Therefore, to exclude the possibility that the massive FeCl 3 -induced oxidative damage produces unphysiological conditions which may artificially favor FXII-dependent contact phase activation, the function of FXII was assessed in a second well-established arterial thrombosis model where injury is induced mechanically in the aorta and blood flow is monitored with an ultrasonic flow probe. After a transient increase directly after injury, blood flow progressively decreased for several minutes in all mice tested.
- FXII is crucial for arterial thrombus formation and may, therefore, serve as an antithrombotic target.
- mice were treated with 2 mg/kg body weight polyclonal rabbit anti-mouse FXII antibodies or non-immune rabbit antibodies and assessed platelet recruitment and thrombus formation in mesenterial arteries following FeCl 3 -induced injury.
- platelet adhesion at sites of injury was comparable in both groups of mice.
- thrombi >20 ⁇ m had formed within 10 min after injury and all of the vessels completely occluded within the observation period ( Figure 6B, C ), thrombi >20 ⁇ m were only observed in 67% of the vessels and occlusion occurred only in 50% of the vessels of the animals treated with anti-FXII antibody.
- FXII has been regarded as an antithrombotic rather than a prothrombotic enzyme based on a few reports showing an association of FXII-deficiency with an increased incidence of venous thrombosis ( Kuhli,C., Scharrer,I., Koch,F., Ohrloff,C., and Hattenbach,L.O. (2004).
- Factor XII deficiency a thrombophilic risk factor for retinal vein occlusion. Am. J. Ophthalmol. 137, 459-464 ; Halbmayer,W.M., Mannhalter,C., Feichtinger,C., Rubi,K., and Fischer,M. (1993).
- FXII-deficient mice display normal bleeding times ( Figure 1A ) and do not show signs of spontaneous or increased posttraumatic (intraoperative) bleeding confirming that FXII is dispensable for normal hemostasis.
- Figure 1A normal bleeding times
- these results seem to contradict with a central dogma of hemostasis that only those factors whose deficiency is associated with bleeding or thrombosis are relevant to blood clotting.
- the data do not challenge this theorem but rather raise the interesting possibility that hemostasis and arterial thrombosis may occur through different mechanism.
- Atherosclerotic lesions are rich in thrombogenic constituents, most importantly TF and fibrillar collagens.
- TF and fibrillar collagens In the process of atherogenesis, enhanced collagen synthesis by intimal smooth muscle cells and fibroblasts has been shown to significantly contribute luminal narrowing. Plaque rupture or fissuring results in exposure of collagen fibrils to the flowing blood which triggers platelet adhesion and aggregation. In addition, they induce FXII activation as shown here for fibrillar collagen type I, which is the major collagen type found in the vessel wall.
- collagens are likely not the only (patho)physiological activator of FXII at sites of injury.
- Other candidates could be substances liberated from disintegrating cells or exposed in the ECM including HSP90 or soluble and insoluble polyanions, e.g. nucleosomes or glycosaminoglycans.
- collagens are by far most thrombogenic because they also potently activate platelets.
- platelets tether to the ECM by the reversible interaction of platelet GPIb-V-IX with collagen-bound vWf which reduces the velocity of the cells and thereby allows binding of other receptors.
- the collagen receptor GPVI is of central importance as it activates integrins ⁇ 2 ⁇ 1 and ⁇ IIb ⁇ 3 which then mediate stable adhesion and contribute to cellular activation.
- platelet activation through the GPVI/FcR ⁇ -chain complex induces a procoagulant state of the cells which is characterized by the exposure of phosphatidylserine (PS) and the production of (PS exposing) membrane blebs and microvesicles.
- PS phosphatidylserine
- Integrin ⁇ 2 ⁇ 1 facilitates this process directly by "outside-in” signals and indirectly by reinforcing GPVI-collagen interactions. It is established that PS-containing membranes strongly accelerate two central reactions of the coagulation process, the tenase and prothrombinase reactions.
- the present invention shows that procoagulant platelets facilitate FXII-dependent clotting in vitro by a mechanism involving both the GPVI/FcR ⁇ -chain complex as well as ⁇ 2 ⁇ 1 ( Figure 2 ). This could at least partly explain why ⁇ 2 ⁇ 1-deficient mice, despite unaltered platelet adhesion at sites of arterial injury, show partial defects in the formation of occlusive thrombi. Besides collagens, coagulating plasma potently stimulates platelet procoagulant activity by an integrin ⁇ IIb ⁇ 3-dependent mechanism.
- ⁇ IIb ⁇ 3 blockade almost completely inhibited platelet participation in FXII-dependent clotting, indicating that the well-known anticoagulant activity of ⁇ IIb ⁇ 3 antagonists may partly be based on the inhibition of the FXII-driven intrinsic coagulation pathway.
- the present invention indicates that the FXII-driven contact system and platelet activation may be mutually dependent processes that cooperate in pathological thrombus formation.
- Fibrinolysis 8, 134-144 Pauer,H.U., Renne,T., Hemmerlein,B., Legler,T., Fritzlar,S., Ad-ham,I., Muller-Esterl,W., Emons,G., Sancken,U., Engel,W., and Burfeind,P. (2004). Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb. Haemost.
- FcR gamma chain deletion results in pleiotrophic effector cell defects.
- Cell 76, 519-529 were from (Taconics, Germantown).
- Total cellular RNA was isolated from a liver of a 129sv wt mouse and the FXII-cDNA synthesis was performed with the "one-step RT-PCR Kit" from Qiagen according to the manufacturers instructions.
- the factor FXII heavy chain (positions 61-1062, corresponding to residues 21-354) was amplified using 25 pmol each of the 5- and 3-primers (ttggatccccaccatggaaagactccaag and ttgaattcgcgcatgaacgaggaca g) introducing a BamH I and EcoR I restriction site, respectively with the following protocol: 30 s at 95 °C, 60 s at 58 °C, and 1 min at 72 °C for 30 cycles on a thermal cycler (Biometra, Göttingen, Germany).
- the PCR product was cloned into the BamH I and EcoR I site of the pGEX-2T expression vector (Pharmacia). Following sequencing protein was expressed in E.coli strain BL21. Exponentially growing bacteria were stimulated with 0.5 mM isopropyl- ⁇ -D-thiogalactopyranoside for 1 h, harvested, resuspended in 10 mM Tris-HCl, pH 7.4, containing 1 mM EDTA, 200 mM NaCl, 10 ⁇ g/ml benzamidine hydrochloride, 10 ⁇ g/ml phenylmethylsulfonyl fluoride and sonicated for 3 min in pulses of 15 s each.
- mice were bled under ether anesthesia from the retroorbital plexus. Blood was collected in a tube containing 20 U/mL heparin, and platelet rich plasma (prp) was obtained by centrifugation at 300 g for 10 min at room temperature (RT).
- prp platelet rich plasma
- prp was centrifuged at 1000 g for 8 min and the pellet was resuspended twice in modified Tyrodes-Hepes buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM Hepes, 5 mM glucose, 0.35% bovine serum albumin, pH 6.6) in the presence of prostacyclin (0.1 ⁇ g/ml) and apyrase (0.02 U/mL). Platelets were then resuspended in the same buffer (pH 7.0, 0.02 U/mL of apyrase) and incubated at 37°C for at least 30 min before analysis.
- modified Tyrodes-Hepes buffer 134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM Hepes, 5 mM glucose, 0.35% bovine serum albumin, pH 6.6
- Heparinized whole blood was diluted 1:20 with modified Tyrode-HEPES buffer (134 mM NaCl, 0.34 mM Na2HP04, 2.9 mM KCl, 12 mM NaHC03, 20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH 7.0) containing 5 mM glucose, 0.35% bovine serum albumin (BSA), and 1 mM CaCl2.
- modified Tyrode-HEPES buffer 134 mM NaCl, 0.34 mM Na2HP04, 2.9 mM KCl, 12 mM NaHC03, 20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH 7.0
- BSA bovine serum albumin
- mice were anesthetized by intraperitoneal injection of tribromoethanol (Aldrich) (0.15 ml/10g of body weight) and 3 mm segment of the tail tip was cut off with a scalpel. Tail bleeding was monitored by gently absorbing the bead of blood with a filter paper without contacting the wound site. When no blood was observed on the paper after 15 second intervals, bleeding was determined to have ceased. When necessary, bleeding was stopped manually after 20 minutes. Where indicated, mice were treated with 100 ⁇ g/mouse of hFXII.
- Mouse blood (1 vol) was collected into 0.5 vol of Hepes buffer containing 20 U/mL heparin. The blood was centrifuged at 250 g for 10 minutes and platelet-rich plasma was gently transferred to a fresh tube. Platelets were labelled with 5-carboxyfluorescein diacetate succinimidyl ester (DCF) and adjusted to a final concentration of 200 x 106 platelets/250 ⁇ l ( Massberg,S., Sausbier,M., Klatt,P., Bauer,M., Pfeifer,A., Siess,W., Fassler,R., Ruth,P., Krombach,F., and Hofmann,F. (1999). Increased adhesion and aggregation of platelets lacking cyclic guanosine 3',5'-monophosphate kinase I. J Exp Med 189, 1255-1264 ).
- DCF 5-carboxyfluorescein diacetate succinimidyl ester
- mice Male and female mice in the age of 4-5 weeks were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol and 2-methyl-2-butanol (Sigma) (0.15 ml/10g of body weight from 2.5% solution). Fluorescently labeled platelets were injected intravenously. Mesentery was exteriorized gently through a midline abdominal incision. Arterioles (35 - 50 ⁇ m diameter) were visualized with a Zeiss Axiovert 200 inverted microscope (x10) equipped with a 100-W HBO fluorescent lamp source and a CCD camera (CV-M300) connected to an S-VHS video recorder (AG-7355, Panasonic, Matsushita Electric, Japan).
- mice were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol and 2-methyl-2-butanol (Aldrich) (0.15 ml/10g of body weight from 2.5% solution).
- Anesthetized mice received a mixture of collagen (0.8 mg/kg) and epinephrine (60 ⁇ g/kg) injected into the jugular vein. The incisions of surviving mice were stitched, and they were allowed to recover. Necroscopy and histological studies were performed on lungs fixed in 4% formaldehyde and paraffin sections were stained with hematoxylin/eosin.
- mice The abdominal cavity of anesthetized mice was longitudinally opened and the abdominal aorta was prepared. An ultrasonic flow probe was placed around the aorta and thrombosis was induced by one firm compression with a forceps. Blood flow was monitored until complete occlusion occurred. The experiment was stopped manually after 45 minutes. Where indicated, human Factor XII was substituted intravenously directly before the experiment.
- mice were sacrificed, lungs rapidly removed and fixed at 4 C for 24 hr in buffered 4% formalin (pH 7.4; Kebo). Tissues were dehydrated and imbedded in paraffin (Histolab Products AB), cut into 4 ⁇ m sections, and mounted. After removal of the paraffin, tissues were stained with Mayers hematoxylin (Histolab Products AB) and eosin (Surgipath Medical Industries, Inc.).
- Thrombin generation was measured according to the method of Aronson et al. (Circulation, 1985), with slight modifications. Platelet-rich or platelet free plasma aliquots (0.5 ml) were placed into round-bottomed polypropylene tubes that were coated with Horms type collagen (100 ⁇ g/ml, 24h, 4°C), and 20 ⁇ l of 1 M Ca2+ was added to initiate clotting. Samples (10 ⁇ l) were added to the wells of a microtiter plate containing 90 ⁇ l of 3.8% sodium citrate at 2.5-10 min intervals for 60 min.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
- The subject of the present invention is, in the most general aspect, the prevention of the formation and/or stabilization of three-dimensional arterial or venous thrombi.
- In particular the present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII activity and preventing the formation and/or the stabilization of thrombi and thrombus growth. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
- Vessel wall injury triggers sudden adhesion and aggregation of blood platelets, followed by the activation of the plasma coagulation system and the formation of fibrin-containing thrombi, which occlude the site of injury. These events are crucial to limit posttraumatic blood loss but may also occlude diseased vessels leading to ischemia and infarction of vital organs. In the waterfall or cascade model, blood coagulation proceeds by a series of reactions involving the activation of zymogens by limited proteolysis culminating in the fulminant generation of thrombin, which converts plasma fibrinogen to fibrin and potently activates platelets. In turn, collagen- or fibrin-adherent platelets facilitate thrombin generation by several orders of magnitude by exposing procoagulant phosphatidyl serine (PS) on their outer surface which propagates assembly and activation of coagulation protease complexes and by direct interaction between platelet receptors and coagulation factors.
- Two converging pathways for coagulation exist that are triggered by either extrinsic (vessel wall) or intrinsic (blood-borne) components of the vascular system. The "extrinsic" pathway is initiated by the complex of the plasma factor VII (FVII) with the integral membrane protein tissue factor (TF), an essential coagulation cofactor that is absent on the luminal surface but strongly expressed in subendothelial layers of the vessel. TF expressed in circulating microvesicles might also contribute to thrombus propagation by sustaining thrombin generation on the surface of activated platelets.
- The "intrinsic" or contact activation pathway is initiated when factor XII (FXII, Hageman factor) comes into contact to negatively charged surfaces in a reaction involving high molecular weight kininogen and plasma kallikrein. FXII can be activated by macromolecular constituents of the subendothelial matrix such as glycosaminoglycans and collagens, sulfatides, nucleotides and other soluble polyanions or non-physiological material such as glass or polymers. One of the most potent contact activators is kaolin and this reaction serves as the mechanistic basis for the major clinical clotting test, the (activated) partial thromboplastin time (PTT, aPTT). In reactions propagated by platelets, activated FXII then activates FXI and FXIa in turn activates factor IX. Despite its high potency to induce blood clotting in vitro, the (patho)physiological significance of the FXII-triggered intrinsic coagulation pathway is questioned by the fact that hereditary deficiency of FXII as well as of high molecular weight kininogen and plasma kallikrein is not associated with bleeding complications. Together with the observation that humans and mice lacking extrinsic pathway constituents, such as TF, FVII or factor IX, suffer from severe bleeding this has lead to the current hypothesis that fibrin formation is in vivo exclusively initiated by the extrinsic cascade (Mackman,N. (2004). Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler. Thromb. Vasc. Biol. 24, 1015-1022).
- Like all physiological mechanisms, the coagulation cascade can become activated inappropriately and result in the formation of haemostatic plugs inside the blood vessels. Thereby, vessels can become blocked and the blood supply to distal organs limited. This process is known as thromboembolism and is associated with high mortality. In addition, the use of prosthetic devices that are in contact with blood is severely limited because of activation of the coagulation cascade and coating of the prosthetic surface, often compromising its function. Examples of such prosthetic devices are haemodialysers, cardiopulmonary by-pass circuits, vascular stents and in-dwelling catheters. In cases where such devices are used, anticoagulants, such as heparin, are used to prevent fibrin from depositing on the surface. However, some patients are intolerant of heparin, which can cause heparin induced thrombocytopenia (HIT) resulting in platelet aggregation and life threatening thrombosis. Furthermore, an intrinsic risk of all anticoagulants used in clinics is an associated increased risk of serious bleeding. Therefore, a need for new types of anticoagulant exists that is not associated with such complications and that can be used in affected patients or as superior therapy concept preventing thrombosis without increased bleeding tendencies.
- Hence, it is apparent that there still exists a need for an improved medication for the treatment or prophylaxis of thrombosis and similar disorders. Therefore, it is an object of the present invention to satisfy such a need. For more than five decades it has been known that deficiency of coagulation factor XII is not associated with increases spontaneous or injury related bleeding complications (Ratnoff, O.D. & Colopy, J.E. (1955) A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 34, 602-13). Indeed, although presenting a pathological aPTT (a clinical clotting test that addresses the intrinsic pathway of coagulation) humans that are deficient in FXII do not suffer from abnormal bleeding even during major surgical procedures (Colman, R. W. Hemostasis and Thrombosis. Basic principles & clinical practice (eds. Colman R. W., Hirsch. J., Mader V. J., Clowes A. W., & George J.) 103-122 (Lippincott Williams & Wilkins, Philadelphia, 2001). In contrast, deficiency of FXII had been associated with increased risk of venous thrombosis (Kuhli, C., Scharrer, I., Koch, F., Ohrloff, C. & Hattenbach, L.O. (2004) Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am. J. Ophthalmol. 137, 459-464., Halbmayer, W.M., Mannhalter, C., Feichtinger, C., Rubi, K. & Fischer, M. (1993) Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction. Wien. Med. Wochenschr. 143, 43-50.). Studies and case reports supporting this idea refer to the index case for FXII deficiency, Mr. John Hageman, who died of pulmonary embolism. The hypothesis that FXII deficiency is associated with an increased prothrombotic risk is challenged by a recent reevaluation of several case reports linking FXII deficiency with thrombosis (Girolami, A., Randi, M.L., Gavasso, S., Lombardi, A.M. & Spiezia, F. (2004) The Occasional Venous Thromboses Seen in Patients with Severe (Homozygous) FXII Deficiency are Probably Due to Associated Risk Factors: A Study of Prevalence in 21 Patients and Review of the Literature. J. Thromb. Thrombolysis 17, 139-143). In most cases the authors identified concomitant congenital or acquired prothrombotic risk factors in combination with factor FXII deficiency that could be responsible for the thrombotic event independently of FXII. The largest epidemiological studies using well characterized patients (Koster, T., Rosendaal, F.R., Briet, E. & Vandenbroucke, J.P. (1994) John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br. J. Haematol. 87, 422-424) and FXII-deficient families (Zeerleder, S. et al. (1999) Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency-a study on 73 subjects from 14 Swiss families. Thromb. Haemost. 82, 1240-1246) indicated that there is no correlation of FXII deficiency and any pro- or anti-thrombotic risk.
- Pixley, R.A. et al. (J. Clin. Invest. 91. 61-68 (1993)) discloses an antifactor XII mAb (mAb C6B7) to block the activation of factor XII and subsequently the activation of the remaining contact system in vivo in a lethal hypotensive bacteremic baboon model. Treatment with this mAb did not affect disseminated intravascular coagulation (DIC). Stassen et al (Thrombosis & Haemostasis, vol. 74, no. 2, 1995-01-01, pages 655-659) describes in vivo anti-thrombotic effects of aprotinin and bovine pancreatic trypsin inhibitors mutants
- Surprisingly and in contrast to common believe of those skilled in the art the applicant has discovered that the factor XII-driven intrinsic coagulation pathway Is essential for arterial thrombus formation in vivo but not necessary for normal tissue-specific hemostasis. Unexpectedly, these results change the long-standing concept that blood clotting in vivo is exclusively mediated by the extrinsic pathway and place factor XII in a central position in the process of pathological thrombus formation.
- Accordingly, the subject of the invention is the use of at least one antibody for inhibiting factor XII and preventing the formation and/or the stabilization of three-dimensional arterial or venous thrombi. The anti-FXII antibody respective inhibitor may hereby function so as inhibiting the activation of FXII and/or interfere with other portions of the FXII molecule that are critically involved in FXII activation.
- Together with the fact that the intrinsic pathway is not required for hemostasis, this establishes factor XII as a promising new target for powerful antithrombotic therapy. In addition these results are important for the development of anti-FXII agents to control other contact system-linked (patho)mechanisms such as inflammation, complement activation, fibrinolysis, angiogenesis and kinin formation.
- Therefore, the present invention further provides the use of such an antibody in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i. e. stroke or myocardial infarction.
- In particular, the use of at least one anti-FXII antibody (e.g. like F1 antibody (MoAb F1, Ravon et al., Blood. 1995 )) to inhibit FXII-driven thrombus formation is according to the present invention.
- A pharmaceutical formulation is provided comprising at least one antibody, which is suitable for inhibiting factor XII and which prevents the formation and/or the stabilization of three-dimensional arterial or venous thrombi.
- In particular, the antibody used for the pharmaceutical formulation is an anti-FXII antibody (e.g. like F1 antibody (MoAb F1, Ravon et al., Blood. 1995 )).
- The antibody may also be a fragment of same or mimetic retaining the inhibitory activity, for example analogues of Kunitz Protease Inhibitor domain of amyloid precursor protein as disclosed in
US Patent 6,613,890 especially in columns 4 through 8. Other suitable inhibitors may be Hamadarin as disclosed by Harahiko Isawa et al. in The Journal of Biological Chemistry, Vol. 277, No. 31 (August 2, pp. 27651 - 27658, 2002). A suitable Com Trypsin inhibitor and methods of its production are disclosed in Zhi-Yuan Chen et al., Applied and Environmental Microbiology, March 1999, p. 1320 - 1324 and reference 19 cited ibidem. Last not least, small molecules isolated for example via use of FXII respective FXIIa inhibition as the assay on which selection is based are part of the invention, as well as their respective use described above or below. These small molecule FXIIa inhibitors could be designed on the bases of a crystal structure of FXII. Therefore several FXII domains or the light chain could be expressed recombinantly in expression systems such as E. coli, yeast or mammalian cells. Then the protein is purified and crystallized using standard procedures as described for the FXII substrate FXI (Jin L, et al. (2005) Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions. J Biol Chem. 280(6):4704-12.) Alternatively, small molecule serine protease inhibitors could be included to stabilize the FXII structure. Such formulations comprising small molecule inhibitors of protein targets, which can be for example designed guided by crystals of these target proteins, are well known in the art and include pharmaceutical formulations that may be, for example, administered to a patient systemically, such as parenterally, or orally or topically. - The term "parenteral" as used here includes subcutaneous, intravenous, intramuscular, intra-arferial and intra-tracheal injection, instillation, spray application and infusion techniques. Parenteral formulations are preferably administered intravenously, either in bolus form or as a constant infusion, or subcutaneously, according to known procedures. Preferred liquid carriers, which are well known for parenteral use, include sterile water, saline, aqueous dextrose, sugar solutions, ethanol, glycols and oils.
- Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants and wetting agents, etc. Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs or the like, or may be presented as a dry product for reconstitution with water or other suitable vehicle for use. Such liquid preparations may contain conventional additives, such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.
- Formulations suitable for topical application may be in the form of aqueous or oily suspensions, solutions, emulsions, gels or, preferably, emulsion ointments. Formulations useful for spray application may be in the form of a sprayable liquid or a dry powder.
- The use of factor XII as an anti-thrombotic target by inhibiting factor XII by at least one antibody and/or one inhibitor and preventing therefore the formation and/or the stabilization of three-dimensional thrombi in the vessel is provided.
- The nature, benefit, and further features of the present invention become apparent from the following detailed description of the performed experiments and their results when read in conjunction with the accompanying figures described below.
- Factor XII-deficient mice were used to analyze the function of the intrinsic coagulation cascade in hemostasis and thrombosis. Intravital fluorescence microscopy and ultrasonic flow measurements revealed a severe defect in the formation and stabilization of three-dimensional thrombi in different arterial branches of the vascular system. Reconstitution of the mutant mice with human factor XII restored the intrinsic coagulation pathway in vitro and arterial thrombus formation in vivo. Mechanistically, the procoagulant activity of the intrinsic pathway was critically promoted by activated platelets. These results place the FXII-induced intrinsic blood coagulation cascade in a central position in the process of arterial thrombus formation linking plasmatic coagulation with platelet aggregation.
-
Figure 1 describes the coagulation analysis of FXII deficient mice: (A) Tail bleeding times of wild-type (n=12) and FXII-/- (n=11) mice. Each symbol represents one individual. (B) Peripheral blood counts in thousands/µl and global coagulation parameters of FXII-/- and wt mice. The abbreviations are white blood counts (WBC), activated partial thromboplastin time (aPTT) and prothrombin time (PT). Values give mean values ± SD of 10 mice of each genotype. (C) Contact system proteins FXII, plasma kallikrein (PK) and high molecular weight kininogen (HK) probed in 0.3 µl wt and FXII-/- plasma by Western blotting using specific antibodies. A molecular weight standard is given on the left. (D) Recalcification clotting times were determined in platelet free (upper panel) and platelet rich (lower panel) plasma from C57BU6 and 129sv wt, FXII-/-, FcRγ-/- and integrin α2-deficient mice following activation with kaolin (dark columns) or collagen (light columns). The effect of JON/A was analyzed in C57BU6 plasma supplemented with 50 µg/ml antibody. Means ± STD from 6 experiments are given. -
Figure 2 . (A) Thromboembolic mortality was observed following the intravenous injection of collagen (0.8 mg/kg) and epinephrine (60µg/kg). All wild-type mice died within 5 min. Animals that were alive 30 min after challenge were considered survivors. (B) Platelet counts in control (n = 19), FXII-/- (n = 14) and FcR γ-/- (n = 5)mice 2 min after infusion of collagen/epinephrine. (C) Heparinized platelet rich plasma from wild-type and FXII-/- mice was stimulated with collagen (10µg/ml) or ADP (5µM) and light transmission was recorded in a standard aggregometer. The results shown are representative of six mice per group. (D) Hematoxilin/Eosinstained sections from lungs of the indicatedmice 2 min after collagen/epinephrine injection. Thrombi per eyefield ware counted in 20 x magnification. The bars represent means ± SDT from 100 eyefields. -
Figure 3 describes the defective thrombus formation in mice lacking factor XII in vivo. Thrombus formation in vivo was monitored on mesenteric arterioles upon injury induced with 20% FeCl3. (A) Single platelet adhesion is detected 5 min after injury in all mouse strains, 7 to 8 minutes after injury the first thrombi in wt mice were observed, whereas in FXII-/- the first thrombi occurred 14 to 35 minutes after injury and in FXI-/- 5 to 35 minutes after injury. (B) Thrombus formation was observed in 100% of mesenteric arteries in wild type mice, but only in 50% of FXII-/- mice and in 44.4% of FXI-/- mice. (C) Thrombi formed in wt mice occluded the vessel in average 25 minutes after injury whereas thrombi formed in FXII and FXI deficient mice did not lead to occlusion. Each symbol represents one single monitored arteriole. (D) Representative pictures of one experiment. -
Figure 4 . (A) Wild-type (n=10), FXII-/-(n= 10) and FXI-/-(n= 11) were analyzed in an arterial occlusion model. Thrombosis was induced in the aorta by one firm compression with a forceps. Blood flow was monitored with an perivascular ultrasonic flow probe until complete occlusion. The experiment was stopped after 40 min. Each symbol represents one individual. (B) Mechanical injury in the carotid artery was induced by a ligation. After removal of the filament thrombus area in wild-type (n= 10) and FXII-/- (n= 10) was measured in µm2. (C) The photomicrographs showrepresentative images 2 min after injury. -
Figure 5 describes the defect in thrombus formation in FXII deficient animals which is restored by human FXII. (A) Thrombus formation upon FeCl3 induced injury was observed in 100% of mesenteric arteries in wild-type mice as well as in FXII-/- mice injected with human FXII. (B) Formed thrombi occluded the vessel in average 25 minutes after injury in wild-type mice and in 22.7 minutes after injury in FXII-/- mice injected with human FXII. Each symbol represents one individual. (C) Representative pictures are shown. (D) FXII-/- mice received 2 mg/kg hFXII-/- and thrombosis was induced in the aorta by one firm compression with a forceps. Blood flow was monitored with an perivascular ultrasonic flow probe until complete occlusion. The experiment was stopped after 40 min. Each symbol represents one individual. -
Figure 6 describes the anti-FXII antibodies inhibiting thrombus formation in mice in vivo. Wild-type mice received 2 mg/kg anti-FXII antibodies or non-immune IgG i.v.. After 15 min, thrombus formation in vivo was monitored on mesenteric arterioles upon injury induced with 20% FeCl3. (A) Single platelet adhesion is detected 5 min after injury in both groups. After 7 to 8 minutes the first thrombi mice in control IgG-treated mice were observed, whereas in anti-FXII-treated mice the first thrombi occurred 12 to 32 minutes after injury. (B) Thrombus formation was observed in 100% of mesenteric arteries in control mice, but only in 60% of anti-FXII-treated mice. (C) Time to complete occlusion is shown. Each symbol represents one individual. -
Figure 7 describes a revised model of arterial thrombus formation. Initially, at sites of vascular lesions thrombin formation is predominantly due to tissue factor (TF) exposure in the subendothelial matrix. TF in complex with FVII initiates the extrinsic pathway of coagulation. At the site of injury the contribution of the FXII driving the intrinsic pathway via FXI for thrombin (FII) generation is minor and negligible for normal hemostasis. Accordingly individuals with FXII-deficiency do not suffer from bleeding. Generated thrombin initiates clot formation by forming fibrin and activating platelets. Propagation of thrombus growth: On surfaces exposed in the growing thrombus the FXII- induced intrinsic pathway critically contributes to thrombin generation. Activated FXII generates additional fibrin through FXI. Accordingly, FXII- as well as FXI- deficiency severely impairs thrombus formation. - In the present invention a potential contribution of the intrinsic pathway of coagulation for pathological thrombus formation in vivo was assessed by intravital microscopy- and flow measurement-based models of arterial thrombosis using mice lacking factor XII. While initial adhesion of platelets at sites of injury is not altered in the mutant animals, the subsequent formation and stabilization of three-dimensional thrombi is severely defective. This defect was seen in different branches of the vasculature and could be completely restored by exogenous human factor XII. These findings establish the factor XII-driven intrinsic coagulation pathway as a major link between primary and secondary hemostasis in a revised model of thrombus formation.
- To analyze the function of FXII for clotting in vivo, FXII-deficient mice were generated. FXII-/- mice are healthy, phenotypically indistinguishable from their wild-type littermates, and fertile. Detailed histological and hemostasiological analyses showed no correlates for increased thrombosis or bleeding in FXII-/- mice despite a prolonged aPTT of 68 ± 17 sec and recalcification time of 412 ± 78 sec in retroorbitally collected plasma (wt: 23 ± 4 and 210 ± 31 sec) (Pauer,H.U., et al. (2004). Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb. Haemost. 92, 503-508). Similarly to FXII-deficient humans, FXII-/- mice present with no increased bleeding tendency as indicated by tail bleeding times similar to those found in wild-type animals (369.5 ± 201.7 and 355.9 ± 176.1 sec, respectively, n = 12 per group,
Figure 1A ). Peripheral blood cell counts of mutant mice did not differ from wild-type controls. Notably, the prothrombin time (PT) of FXII-/- mice was similar to the wild-type (8.9 ± 1.3 vs. 9.1 ± 1.3 sec) indicating that FXII deficiency does not affect fibrin formation by the extrinsic coagulation system (Fig 1B ). To assess potential differences in FXII procoagulant activity between humans and mice, FXII-deficient human (FXII < 1%) with murine wild-type plasma or vice versa were reconstituted and the PTT of the mixtures was determined. In either case, clot formation was normalized supporting the notion that FXII function for clotting is comparable in humans and mice. - In humans similarly to FXII deficiency the deficiency of contact system proteins plasma kallikrein (PK) and high molecular weight kininogen (HK) does not result in an increased bleeding risk despite a prolonged aPTT. To confirm that the aPTT prolongation in FXII-/- mice is not due to additional defects of contact phase proteins, we analyzed PK and HK in FXII-/- and wt plasma. The Western blot indicated that HK and PK levels are equivalent in mutant and wild-type mice (
Fig 1 C) . Functionally, in FXII-/- plasma exposed to collagen or kaolin HK procession and thrombin formation was severely impaired compared to wild-type. - Blood coagulation and platelet activation are complementary and mutually dependent processes. Platelets interact with and contribute to the activation of several coagulation factors and the central coagulation product thrombin is a potent platelet activator. Therefore, next the contribution of platelets and FXII was examined to clot formation in more detail. For this, we induced clotting using either kaolin that classically activates FXII but has no direct effect on platelets or collagen, which activates both FXII and platelets where it interacts with numerous receptors, most importantly α2β1 integrin and GPVI. In the presence, but not in the absence of platelets, collagen was superior to kaolin for clot formation in wild-type plasma (
Figure 1 D) . In contrast, in plasma containing activation-defective FcRγ-/- platelets, the relative potency of kaolin and collagen was similar to PFP and a similar effect was seen with PRP from integrin α2-/- mice. Platelet procoagulant activity is also efficiently triggered in coagulating plasma and the fibrin(ogen) receptor αIIbβ3 has been shown to play a crucial role in this process although the underlying mechanisms are not fully understood. In agreement with these reports, the αIIbβ3-function blocking antibody JON/A largely inhibited the platelet-dependent decrease in the clotting time (Figure 1D ). Together, these results demonstrated that platelets in a procoagulant state can promote FXII-induced clot formation. - To test whether collagen-induced FXII activation has functional consequences in vivo, wild-type and FXII-/- mice were subjected to a model of lethal pulmonary thromboembolism induced by the infusion of a mixture of collagen (0.8 mg/kg body weight) and epinephrine (60 µg/kg body weight). All of the control mice (19/19) died within 5 min from widespread pulmonary thrombosis and cardiac arrest which was accompanied by a > 95% reduction in circulating platelet counts as soon as 2 min after challenge (
Figure 2 A, B ). Under these experimental conditions, 35.7% (5/14) of the FXII-/- mice survived although their peripheral platelet counts were similarly reduced as in the wild-type control, suggesting that the observed protection was not based on a platelet activation defect. This assumption was confirmed by in vitro studies showing that FXII-/- platelets express normal levels of the major surface glycoproteins, including collagen receptors, and that the cells are normally activatable by classical agonists such as thrombin, adenosine diphosphate (ADP), or the GPVI-specific agonist, collagen-related peptide (as measured by activation of integrin αIIbβ3 and P-selectin expression). In agreement with this, FXII-/- platelets exhibited an unaltered aggregation response to collagen, ADP (Figure 2C ), PMA, or thrombin. - In a parallel set of experiments, FcRγ-/- mice were challenged with collagen/epinephrine. These mice were completely protected from lethality and platelet counts were only moderately reduced 2 min after challenge confirming the strict requirement for platelet activation for lethality in this model. These data were further supported by histological analysis of lung sections derived from mice of the different groups. While the large majority of the vessels was obstructed in wild-type mice, this was significantly reduced in FXII-/- mice (survivors and non survivors). In agreement with previous reports, virtually no thrombi were found in lungs from FcRγ-/- mice (
Figure 2D ). These results suggested that in vivo collagen triggers both platelet activation and the FXII-dependent intrinsic coagulation pathway which in this model synergize to form occlusive pulmonary thrombi. - Pathological thrombus formation is frequently initiated by fissuring or abrupt disruption of the atherosclerotic plaque in the arterial branch of the vasculature leading to unphysiologically strong platelet activation and procoagulant activity on the surface on the subendothelial layers. To test the role of FXII in these processes, thrombus formation was studied in wild-type and FXII-/- mice, employing different models of arterial injury. In the first model, oxidative injury was induced in mesenteric arterioles (60 - 100 µm in diameter) and thrombus formation was examined by in vivo fluorescence microscopy. Wild-type and FXII-/- mice received fluorescently labeled platelets (1 x 108) of the same genotype and injury was induced by topical application of a filter paper saturated with 20% ferric chloride (FeCl3) for 1 min which provokes the formation of free radicals leading to the disruption of the endothelium. Platelet interactions with the injured vessel wall started rapidly and five minutes after injury the number of firmly adherent platelets was similar in both groups of mice (
Figure 3A ). However, while in wild-type mice the adherent platelets consistently recruited additional platelets from the circulation, resulting in the formation of aggregates, this process was severely defective in the mutant mice. In 100% of the control vessels (17/17), stable thrombi >20 µm in diameter had formed with 10 min after injury which continuously grew over time and finally lead to complete occlusion in 94.1% (16/17) of the vessels within the observation period of 40 min (mean occlusion time: 25.6 ± 8.9 min)(Figure 3 ). In sharp contrast, in mutant mice the formation of microaggregates or thrombi occurred was completely absent in 50 % (7/14) of the vessels. In the remaining 50% (7/14) of the vessels, thrombi were formed which were, however, consistently unstable and rapidly detached from the vessel wall. In none of the vessels, a thrombus >20 µm in diameter remained attached at the site of injury for more than 1 min. Consequently, no vessel occluded in FXII-/- mice within the observation period (40 min). This unexpected result demonstrated that FXII is required for the generation and stabilization of platelet-rich thrombi in FeCl3-injured arterioles and suggested that FXII-induced the coagulation pathway essentially contributes to the observed thrombotic response. This assumption was confirmed when mice deficient in FXI were analysed in the same model. Since FXI is the principal substrate of FXII in the "intrinsic" cascade, a similar defect in thrombus formation would have to be expected in those mice. Indeed, very similar to FXII-/- mice, virtually normal platelet adhesion at the site of injury was detectable during the first three minutes after injury, whereas the formation of thrombi was completely inhibited in 55.6% (5/9) of the vessels. In the remaining vessels, the formed microaggregates and thrombi were unstable and continuously embolized (Figure 3 ). As a result, none of the vessels occluded within the observation period (40 min). This data shows that FXI-deficient mice are protected in a model of FeCl3-induced occlusion of the carotid artery. - FeCl3-induced arterial thrombus formation is known to depend on platelets and thrombin generation but it is unclear how well this type of injury resembles the thrombogenic milieu produced in diseased vessels, e.g. upon rupture of the atherosclerotic plaque. Therefore, to exclude the possibility that the massive FeCl3-induced oxidative damage produces unphysiological conditions which may artificially favor FXII-dependent contact phase activation, the function of FXII was assessed in a second well-established arterial thrombosis model where injury is induced mechanically in the aorta and blood flow is monitored with an ultrasonic flow probe. After a transient increase directly after injury, blood flow progressively decreased for several minutes in all mice tested. In all tested wild-type mice (10/10), this decrease resulted in complete and irreversible occlusion of the vessel within 1.6 to 11.1 min after injury (mean occlusion time 5.3 ± 3.0 min,
Figure 4A ). A different picture was found in FXII-/- mice where stable thrombus formation was severely defective. While in all animals a progressive reduction in blood flow was observed during the first minutes after injury, occlusion occurred only in 4 of 10 mice. Moreover, the occlusive thrombi in those mice were in all cases unstable and rapidly embolized so that blood flow was re-established between 10 s and 115 s after occlusion. None of the re-opened vessels occluded a second time. Consequently, all FXII-/- mice displayed essentially normal flow rates through the injured vessel at the end of the observation period (40 min). Very similar results were obtained with FXI-/- mice, where 9 of 11 were unable to establish an occlusive thrombus within the observation period (30 min)(Figure 5A ). - The severe defect in arterial thrombus formation in FXII-/- mice was confirmed in a third independent model where platelet recruitment in the injured carotid artery was studied by in vivo fluorescence microscopy. Platelets were purified from donor mice, fluorescently labeled and injected into recipient mice of the same genotype. Vascular injury was induced by vigorous ligation of the carotid artery which consistently causes disruption of the endothelial layer and frequently breaching of the internal elastic lamina followed by rapid collagen-triggered platelet adhesion and thrombus formation at the site of injury (Gruner et al., Blood 102:12/8/2005 2003). While wild-type animals rapidly formed large stable thrombi (thrombus area: 102.821 ± 39.344 µm2; t = 5min), which did not embolize, only small and medium-sized aggregates formed in the mutant mice, which were frequently detached from the site of injury (
Figure 4B, C ). Consequently, the thrombus area was dramatically reduced in the mutant mice (8.120 ± 13.900 µm2; t = 5min) although primary platelet adhesion on the vessel wall appeared not to be defective. - To test whether the severe defect in thrombus formation in FXII-/- mice results from the lack of plasma FXII or platelet FXII, or possibly from secondary, unidentified effects of FXII deficiency such as alterations in the vasculature, arterial thrombus formation was studied in FXII-/- mice following administration human of FXII (2 µg/g body weight). This treatment normalized the PTT (27 ± 6 sec) and fully restored arterial thrombus formation. In 100% of the FeCl3-injured mesenterial arterioles, thrombi >20 µm had formed within 10 min after injury and all of the vessels completely occluded within the observation period (
Figure 5A-C ). There was even a tendency towards faster occlusion detectable in the reconstituted FXII-/- mice as compared to untreated wild-type control mice (mean occlusion time: 22.7 ± 8.2 min vs. 25.6 ± 8.9 min). A similar result was obtained when injury was induced mechanically in the aorta. In all tested vessels, complete and irreversible occlusion occurred within 10 min after injury (Figure 5D ), confirming that the lack of plasma FXII accounts for the thrombotic defect observed in FXII-/- mice. - The above-described studies demonstrated that FXII is crucial for arterial thrombus formation and may, therefore, serve as an antithrombotic target.
- To assess this directly, mice were treated with 2 mg/kg body weight polyclonal rabbit anti-mouse FXII antibodies or non-immune rabbit antibodies and assessed platelet recruitment and thrombus formation in mesenterial arteries following FeCl3-induced injury. As shown in
Figure 6A , platelet adhesion at sites of injury was comparable in both groups of mice. However, while in 100% of the control vessels, thrombi >20 µm had formed within 10 min after injury and all of the vessels completely occluded within the observation period (Figure 6B, C ), thrombi >20 µm were only observed in 67% of the vessels and occlusion occurred only in 50% of the vessels of the animals treated with anti-FXII antibody. - Alternatively, to test the impact of small molecule FXII inhibitors, wildtype mice were infused with the FXII inhibitor corn trypsin inhibitor (CTI, 50 µg/g body weight) 5 min prior to FeCl3-induced injury in the carotic artery (Wang et al. (2005) J. Thromb. Heamost. 3: 695-702). Inhibitor treatment prolonged the aPTT (62±11 sec, n=4) but did not affect bleeding during the surgical procedure. In none of the animals tested (0/4) vessel occluding thrombi developed within 30 min following application of FeCl3.
- These results demonstrated that anti-FXII therapeutics like anti-FXII antibodies or small molecule FXII inhibitors provide significant protection against arterial thrombus formation.
- Although contact activation of FXII has been recognized as the starting point of the intrinsic blood coagulation cascade for more than 50 years this pathway was considered to be irrelevant for blood clotting. In the present invention, three different in vivo models were used to analyze platelet recruitment and thrombus formation at sites of arterial injury in FXII-deficient mice by in situ video microscopy and ultrasonic flow measurements and showed a severe inability to form stable three-dimensional thrombi. This defect was based on the lack of FXII in plasma, but not other compartments, as it was completely reversed by intravenous injection of exogenous human FXII (
Figure 6 ) thereby also excluding that secondary effects of FXII deficiency contribute to the observed phenotype. - These results are unexpected as FXII has been regarded as an antithrombotic rather than a prothrombotic enzyme based on a few reports showing an association of FXII-deficiency with an increased incidence of venous thrombosis ( Kuhli,C., Scharrer,I., Koch,F., Ohrloff,C., and Hattenbach,L.O. (2004). Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am. J. Ophthalmol. 137, 459-464; Halbmayer,W.M., Mannhalter,C., Feichtinger,C., Rubi,K., and Fischer,M. (1993). [Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction]. Wien. Med. Wochenschr. 143, 43-50).
- FXII-deficient mice display normal bleeding times (
Figure 1A ) and do not show signs of spontaneous or increased posttraumatic (intraoperative) bleeding confirming that FXII is dispensable for normal hemostasis. At the first sight, these results seem to contradict with a central dogma of hemostasis that only those factors whose deficiency is associated with bleeding or thrombosis are relevant to blood clotting. On a closer look, however, the data do not challenge this theorem but rather raise the interesting possibility that hemostasis and arterial thrombosis may occur through different mechanism. - Although the above discussed mechanisms of sustained thrombin generation may be sufficient to generate a hemostatic plug, the data show that the formation of stable arterial thrombi requires the additional activation of the intrinsic coagulation pathway, at least in mice. There is no evidence for the possibility that species-specific differences exist in the function of FXII or a substrate of the enzyme. All coagulation parameters and the hemostatic phenotype of the mutant mice are in line with human FXII-deficiency and all alterations observed in animals were normalized by reconstitution with human FXII (
Figure 5 ). Furthermore, it is excluded that the thrombotic defect is restricted to a particular experimental model as it was found in different arterial branches of the vasculature and independent of the type of injury. It may be difficult to determine what type of damage best reflects the vascular lesion produced by rupture of an atherosclerotic plaque, which is considered the major trigger of acute cardiovascular syndromes. Atherosclerotic lesions are rich in thrombogenic constituents, most importantly TF and fibrillar collagens. In the process of atherogenesis, enhanced collagen synthesis by intimal smooth muscle cells and fibroblasts has been shown to significantly contribute luminal narrowing. Plaque rupture or fissuring results in exposure of collagen fibrils to the flowing blood which triggers platelet adhesion and aggregation. In addition, they induce FXII activation as shown here for fibrillar collagen type I, which is the major collagen type found in the vessel wall. But the collagens are likely not the only (patho)physiological activator of FXII at sites of injury. Other candidates could be substances liberated from disintegrating cells or exposed in the ECM including HSP90 or soluble and insoluble polyanions, e.g. nucleosomes or glycosaminoglycans. - Among these FXII activators, collagens are by far most thrombogenic because they also potently activate platelets. At sites of injury, platelets tether to the ECM by the reversible interaction of platelet GPIb-V-IX with collagen-bound vWf which reduces the velocity of the cells and thereby allows binding of other receptors. Among these, the collagen receptor GPVI is of central importance as it activates integrins α2β1 and αIIbβ3 which then mediate stable adhesion and contribute to cellular activation. In addition, platelet activation through the GPVI/FcRγ-chain complex induces a procoagulant state of the cells which is characterized by the exposure of phosphatidylserine (PS) and the production of (PS exposing) membrane blebs and microvesicles. Integrin α2β1 facilitates this process directly by "outside-in" signals and indirectly by reinforcing GPVI-collagen interactions. It is established that PS-containing membranes strongly accelerate two central reactions of the coagulation process, the tenase and prothrombinase reactions. The present invention shows that procoagulant platelets facilitate FXII-dependent clotting in vitro by a mechanism involving both the GPVI/FcRγ-chain complex as well as α2β1 (
Figure 2 ). This could at least partly explain why α2β1-deficient mice, despite unaltered platelet adhesion at sites of arterial injury, show partial defects in the formation of occlusive thrombi. Besides collagens, coagulating plasma potently stimulates platelet procoagulant activity by an integrin αIIbβ3-dependent mechanism. In the present experiments, αIIbβ3 blockade almost completely inhibited platelet participation in FXII-dependent clotting, indicating that the well-known anticoagulant activity of αIIbβ3 antagonists may partly be based on the inhibition of the FXII-driven intrinsic coagulation pathway. Together, the present invention indicates that the FXII-driven contact system and platelet activation may be mutually dependent processes that cooperate in pathological thrombus formation. - Based on the experimental results, a model of pathological thrombus formation depicted schematically in
figure 7 was proposed. At sites of vascular injury, the first layer of platelets comes in contact with collagens in an environment that is additionally enriched in TF and fibrin. It is therefore not surprising that platelet adhesion to the damaged vessel wall is not impaired in FXII-/- mice and it is very likely that these cells were fully activated and in a procoagulant state. In a growing thrombus, however, collagens are absent and TF concentrations provided by microvesicles may be lower as compared to the vessel wall and reduced in their activity by TFPI released in large amounts from activated platelets. Under these conditions, additional mechanisms are required to maintain spatio-temporal thrombin generation to activate newly recruited platelets and, via the formation of fibrin provoke their coagulant activity. The severe inability of FXII-/- mice to establish stable thrombi unambiguously demonstrates that the FXII-driven intrinsic coagulation pathway is an essential player in this process. Together with the observation that low TF-mice also display impaired arterial thrombosis, these results suggest that both extrinsic and intrinsic pathway must be operative and synergize to promote the formation of a three-dimensional and eventually occluding thrombus. In contrast, the lack of bleeding in FXII-/- mice indicates that thrombus growth in the third dimension may not be necessary to seal a hole in the vessel wall. This could explain why the extrinsic pathway, which produces the first thin layer of fibrin and activated platelets, is sufficient to mediate normal hemostasis. Our results raise the interesting possibility the formation of a three-dimensional thrombus serves functions other than hemostasis. These could include the arrest of blood flow in certain areas of tissue trauma in order to prevent the distribution of invading pathogens or toxins with the blood stream. - All experiments and care were approved by the local Animal Care & Use Committee. Classical mouse mutants lacking factor XI (FXI-/-), factor XII (FXII-/-), α2 integrin (α2-/-) were produced as described ( Gailani,D., Lasky,N.M., and Broze,G.J., Jr. (1997). A murine model of factor XI deficiency. Blood Coagul. ; Pauer,H.U., Renne,T., Hemmerlein,B., Legler,T., Fritzlar,S., Ad-ham,I., Muller-Esterl,W., Emons,G., Sancken,U., Engel,W., and Burfeind,P. (2004). Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb. Haemost. 92, 503-508; Holtkotter,O., Nieswandt,B., Smyth,N., Muller,W., Hafner,M., Schulte,V., Krieg,T., and Eckes,B. (2002). Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem JID - 2985121 R 277, 10789-10794). As a control C57B/6J mice (FXI-/-) or Sv129 (FXII-/-) were used. Mice deficient in the FcRγ-chain ( Takai,T., Li,M., Sylvestre,D., Clynes,R., and Ravetch,J.V. (1994). FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76, 519-529) were from (Taconics, Germantown).
- Total cellular RNA was isolated from a liver of a 129sv wt mouse and the FXII-cDNA synthesis was performed with the "one-step RT-PCR Kit" from Qiagen according to the manufacturers instructions. The factor FXII heavy chain (positions 61-1062, corresponding to residues 21-354) was amplified using 25 pmol each of the 5- and 3-primers (ttggatccccaccatggaaagactccaag and ttgaattcgcgcatgaacgaggaca g) introducing a BamH I and EcoR I restriction site, respectively with the following protocol: 30 s at 95 °C, 60 s at 58 °C, and 1 min at 72 °C for 30 cycles on a thermal cycler (Biometra, Göttingen, Germany). The PCR product was cloned into the BamH I and EcoR I site of the pGEX-2T expression vector (Pharmacia). Following sequencing protein was expressed in E.coli strain BL21. Exponentially growing bacteria were stimulated with 0.5 mM isopropyl-β-D-thiogalactopyranoside for 1 h, harvested, resuspended in 10 mM Tris-HCl, pH 7.4, containing 1 mM EDTA, 200 mM NaCl, 10 µg/ml benzamidine hydrochloride, 10 µg/ml phenylmethylsulfonyl fluoride and sonicated for 3 min in pulses of 15 s each. After centrifugation at 15,000 x g for 20 min at 4 °C, the supernatant was removed and transferred to a GST-sepharose column (Pharmacia) for purification. Eluted protein was > 95% pure as deduced from Coomassie stained SDS-PAGE. Polyclonal antibodies against GST-heavy chain FXII were raised in rabbits following standard procedures. Antibodies were selected from the hyperimmunserum using columns with FXII-heavy chain fused to the maltose binding protein (MBP). These fusion proteins were expressed and purified using the pMAL-c2 expression system and amylose resin columns similarly as described for the GST-fusion construct.
- Mice were bled under ether anesthesia from the retroorbital plexus. Blood was collected in a tube containing 20 U/mL heparin, and platelet rich plasma (prp) was obtained by centrifugation at 300 g for 10 min at room temperature (RT). For washed platelets, prp was centrifuged at 1000 g for 8 min and the pellet was resuspended twice in modified Tyrodes-Hepes buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM Hepes, 5 mM glucose, 0.35% bovine serum albumin, pH 6.6) in the presence of prostacyclin (0.1 µg/ml) and apyrase (0.02 U/mL). Platelets were then resuspended in the same buffer (pH 7.0, 0.02 U/mL of apyrase) and incubated at 37°C for at least 30 min before analysis.
- Heparinized whole blood was diluted 1:20 with modified Tyrode-HEPES buffer (134 mM NaCl, 0.34 mM Na2HP04, 2.9 mM KCl, 12 mM NaHC03, 20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH 7.0) containing 5 mM glucose, 0.35% bovine serum albumin (BSA), and 1 mM CaCl2. The samples were incubated with fluorophore-labeled antibodies for 15 minutes at room temperature and directly analyzed on a FACScalibur (Becton Dickinson, Heidelberg, Germany) (Nieswandt,B., Schulte,V., and Bergmeier,W. (2004). Flow-cytometric analysis of mouse platelet function. Methods Mol. Biol. 272, 255-268).
- To determine platelet aggregation, light transmission was measured using prp (200 µL with 0.5 x 106 platelets/µL). Transmission was recorded in a Fibrintimer 4 channel aggregometer (APACT Laborgeräte und Analysensysteme, Hamburg, Germany) over 10 min and was expressed as arbitrary units with 100% transmission adjusted with plasma. Platelet aggregation was induced by addition of collagen (10 µg/mL) and ADP (5 µM).
- Mice were anesthetized by intraperitoneal injection of tribromoethanol (Aldrich) (0.15 ml/10g of body weight) and 3 mm segment of the tail tip was cut off with a scalpel. Tail bleeding was monitored by gently absorbing the bead of blood with a filter paper without contacting the wound site. When no blood was observed on the paper after 15 second intervals, bleeding was determined to have ceased. When necessary, bleeding was stopped manually after 20 minutes. Where indicated, mice were treated with 100 µg/mouse of hFXII.
- Mouse blood (1 vol) was collected into 0.5 vol of Hepes buffer containing 20 U/mL heparin. The blood was centrifuged at 250 g for 10 minutes and platelet-rich plasma was gently transferred to a fresh tube. Platelets were labelled with 5-carboxyfluorescein diacetate succinimidyl ester (DCF) and adjusted to a final concentration of 200 x 106 platelets/250µl (Massberg,S., Sausbier,M., Klatt,P., Bauer,M., Pfeifer,A., Siess,W., Fassler,R., Ruth,P., Krombach,F., and Hofmann,F. (1999). Increased adhesion and aggregation of platelets lacking cyclic guanosine 3',5'-monophosphate kinase I. J Exp Med 189, 1255-1264).
- In vivo thrombosis model with FeCl3-induced injury.
- Male and female mice in the age of 4-5 weeks were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol and 2-methyl-2-butanol (Sigma) (0.15 ml/10g of body weight from 2.5% solution). Fluorescently labeled platelets were injected intravenously. Mesentery was exteriorized gently through a midline abdominal incision. Arterioles (35 - 50µm diameter) were visualized with a
Zeiss Axiovert 200 inverted microscope (x10) equipped with a 100-W HBO fluorescent lamp source and a CCD camera (CV-M300) connected to an S-VHS video recorder (AG-7355, Panasonic, Matsushita Electric, Japan). After topical application of FeCl3 (20%) which induced vessel injury and denudation of the endothelium, were arterioles monitored for 40 min or until complete occlusion occurred (blood flow stopped for > 1min). Firm platelet adhesion is determined as number of fluorescently labeled platelets that deposited on the vessel wall until 5 minutes after injury, thrombus is characterized as a platelet aggregate in a diameter larger than 20µm, occlusion time of vessel is characterized as time required for blood to stop flowing for at least one minute. In all experiments maximum of two arterioles were chosen from each mouse based on quality of exposure. A total of 17 wt, 14 FXII-/- and 9 FXI-/- arterioles were studied. - Intravital microscopy of the injured carotid artery was performed essentially as described (Massberg,S., Gawaz,M., Gruner,S., Schulte,V., Konrad,I., Zohlnhofer,D., Heinzmann,U., and Nieswandt,B. (2003). A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med JID - 2985109R 197, 41-49). Briefly, mice were anesthetized by intraperitoneal injection of ketamine/xylazine (
ketamine 100 mg/kg, Parke-Davis, Karlsruhe, Germany; xylazine 5 mg/kg, Bayer AG, Leverkusen, Germany). Polyethylene catheters (Portex, Hythe, England) were implanted into the right jugular vein and fluorescent platelets (200 x 106/250 µl) were infused intravenously. Carotid injury for endothelial denudation was induced by vigorous ligation. Prior to and following vascular injury, the fluorescent platelets were visualized in situ by in vivo video microscopy of the right common carotid artery using a Zeiss Axiotech microscope (20 x water immersion objective, W 20x/0.5, Zeiss, Göttingen, Germany) with a 100 W HBO mercury lamp for epi-illumination. Platelet adhesion and thrombus formation was recorded for 5 min after the induction of injury and the video-taped images were evaluated using a computer-assisted image analysis program (Visitron, Munich, Germany). - Mice were anesthetized by intraperitoneal injection of 2,2,2-tribromoethanol and 2-methyl-2-butanol (Aldrich) (0.15 ml/10g of body weight from 2.5% solution). Anesthetized mice received a mixture of collagen (0.8 mg/kg) and epinephrine (60 µg/kg) injected into the jugular vein. The incisions of surviving mice were stitched, and they were allowed to recover. Necroscopy and histological studies were performed on lungs fixed in 4% formaldehyde and paraffin sections were stained with hematoxylin/eosin.
- Platelet count was determined by flow cytometry on a FACScalibur (Becton Dickinson, Heidelberg, Germany). Results are expressed as mean ± S.D or as percent of control (wt, n = 19; FXII-/-, n = 14 and FcRγ-/-, n = 5).
- The abdominal cavity of anesthetized mice was longitudinally opened and the abdominal aorta was prepared. An ultrasonic flow probe was placed around the aorta and thrombosis was induced by one firm compression with a forceps. Blood flow was monitored until complete occlusion occurred. The experiment was stopped manually after 45 minutes. Where indicated, human Factor XII was substituted intravenously directly before the experiment.
- Mice were sacrificed, lungs rapidly removed and fixed at 4 C for 24 hr in buffered 4% formalin (pH 7.4; Kebo). Tissues were dehydrated and imbedded in paraffin (Histolab Products AB), cut into 4µm sections, and mounted. After removal of the paraffin, tissues were stained with Mayers hematoxylin (Histolab Products AB) and eosin (Surgipath Medical Industries, Inc.).
- Plasma (0,3µl/lane) was separated by 12.5% (w/v) polyacrylamide gel electrophoresis in the presence of 1% (w/v) SDS (Laemmli, 1970). Proteins were transferred onto nitrocellulose membranes for 30 min at 100mA. The membranes were blocked with PBS containing 4% (w/v) dry milk powder and 0.05% (w/v) Tween-20, pH 7.4. Membranes were probed with 0.5µg/ml of the monoclonal antibody against MBK3 (Haaseman J. Immunology 1988). Bound antibodies were detected using peroxidase-conjugated secondary antibodies against mouse IgG (dilution 1:5000) followed by a chemiluminescence detection method.
- For the determination of the recalcification clotting time, 100 µl citrate anticoagulated mouse plasma (0.38% sodium citrate), was incubated with 100 µl each of Horm type collagen (Nycomed, München, Germany), ellagic acid, chondroitin sulfate (both from Sigma), kaolin or buffer (
final concentrations 30 µg/ml) for 120 sec at 37°C in a KC10 "Kugelkoagulometer" (Amelung, Lemgo, Germany). To test the effect of platelets activation on FXII-dependent clotting washed platelets were resuspended in Tyrode buffer including 4 mM Ca2+ and 5µM Ca2+-ionophor A23187 (Sigma) for 10 min prior to addition to platelet free plasma. Clot formation was initiated by recalcification with 100µl 25 mM CaCl2-solution, and the time until clotting occurred was recorded using the coagulation timer KC4 (Amelung). - Global and single coagulation parameters were determined with an automated blood coagulation system (BCS, Dade Behring) with Dade Behring reagents according to the protocols for human samples detailed by the manufacturer. Principles of BCS assay protocols are available from Dade Behring package inserts, which can be found on Dade Behring's web site (http://www.dadebehring.com). D-dimers werde measured with the ELISA from Asserachrom (Roche). Peripheral blood counts were determines on the Sysmex XE 2100 according to standard protocols.
- Thrombin generation was measured according to the method of Aronson et al. (Circulation, 1985), with slight modifications. Platelet-rich or platelet free plasma aliquots (0.5 ml) were placed into round-bottomed polypropylene tubes that were coated with Horms type collagen (100µg/ml, 24h, 4°C), and 20 µl of 1 M Ca2+ was added to initiate clotting. Samples (10 µl) were added to the wells of a microtiter plate containing 90 µl of 3.8% sodium citrate at 2.5-10 min intervals for 60 min. Color was developed for 2 min by the addition of 50 I of 2 mmol/liter S-2238 (H-D-Phe-Arg-NH-NO2-HCl, a thrombin-specific substrate; Chromogenix, Mölndal, Sweden) in 1 mol/liter Tris (pH 8.1). The absorbance of the released color product was measured spectrophotometrically at a wavelength of 405 nm using a Vmax microtiter plate reader (Easy Reader, EAR 340AT, SLT Lab Instruments GmbH, Vienna, Austria). Measurements were obtained in triplicate at each time point.
- Statistical analysis was performed using the unpaired Student's t test.
Claims (5)
- At least one antibody anti factor XII/XIIa for use in treating a disorder selected from the group consisting of venous or arterial thrombus formation by preventing the formation and/or the stabilization of pathological thrombi and thereby three-dimensional intraluminal thrombus growth related to said disorder.
- The antibody according to claim 1 wherein said antibody is an anti-FXII antibody.
- The antibody according to claim 1 or 2 wherein said antibody is inhibiting FXII activation.
- The antibody according to any one of the claims 1 to 2 wherein said antibody is inhibiting FXIIa.
- The antibody according to any one of the claims 1 to 4 where in the venous or arterial thrombus formation is stroke or myocardial infarction.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05820601A EP1830924B1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
PL05820601T PL1830924T3 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
EP10183075A EP2272565A3 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04030593 | 2004-12-23 | ||
EP05820601A EP1830924B1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
PCT/EP2005/013714 WO2006066878A1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10183075.0 Division-Into | 2010-09-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1830924A1 EP1830924A1 (en) | 2007-09-12 |
EP1830924B1 true EP1830924B1 (en) | 2013-02-27 |
Family
ID=34927953
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05820601A Active EP1830924B1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
EP10183075A Withdrawn EP2272565A3 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10183075A Withdrawn EP2272565A3 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
Country Status (14)
Country | Link |
---|---|
US (3) | US8119137B2 (en) |
EP (2) | EP1830924B1 (en) |
JP (1) | JP5118492B2 (en) |
KR (1) | KR101277097B1 (en) |
CN (1) | CN101102819A (en) |
AU (1) | AU2005318464B2 (en) |
BR (1) | BRPI0519349A8 (en) |
CA (1) | CA2591786C (en) |
DK (1) | DK1830924T3 (en) |
ES (1) | ES2407965T3 (en) |
MX (1) | MX2007006997A (en) |
PL (1) | PL1830924T3 (en) |
RU (1) | RU2514878C2 (en) |
WO (1) | WO2006066878A1 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
ES2709103T3 (en) | 2002-08-28 | 2019-04-15 | Dyax Corp | Methods to preserve organs and tissues |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
GB0607515D0 (en) * | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
EP2109457B1 (en) | 2007-02-12 | 2016-01-06 | CSL Behring GmbH | Therapeutic application of kazal-type serine protease inhibitors |
US20090105142A1 (en) * | 2007-08-23 | 2009-04-23 | Genzyme Corporation | Treatment with kallikrein inhibitors |
US20110154517A1 (en) * | 2007-10-22 | 2011-06-23 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
EP2145900A1 (en) | 2008-07-15 | 2010-01-20 | CSL Behring GmbH | Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation |
EP2103311A1 (en) | 2008-03-20 | 2009-09-23 | CSL Behring GmbH | The calcium sensor STIM1 is essential for pathological thrombus formation |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
EP2269597A1 (en) | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
EP2272874A1 (en) | 2009-07-10 | 2011-01-12 | CSL Behring GmbH | Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
RS62853B1 (en) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins |
EP2371857A1 (en) * | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
WO2012064758A2 (en) * | 2010-11-08 | 2012-05-18 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
CA2829037C (en) | 2011-03-09 | 2022-05-17 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
WO2013014092A1 (en) | 2011-07-22 | 2013-01-31 | Csl Behring Gmbh | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
BR112014003787A2 (en) * | 2011-08-23 | 2020-10-27 | Synapse B.V. | thermostable blood coagulation system activation inhibitors by contact with foreign surfaces |
EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
US9574013B2 (en) * | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
JP2017501968A (en) * | 2013-06-28 | 2017-01-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Combination therapy using factor XII inhibitor and C1-inhibitor |
WO2015193457A1 (en) * | 2014-06-18 | 2015-12-23 | Csl Behring Gmbh | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
CN107405399B (en) | 2015-01-02 | 2022-02-08 | 武田药品工业株式会社 | Bispecific antibodies against plasma kallikrein and factor XII |
WO2016174103A1 (en) * | 2015-04-28 | 2016-11-03 | Ecole polytechnique fédérale de Lausanne (EPFL) | Novel inhibitors of the enzyme activated factor xii (fxiia) |
CA2993026A1 (en) | 2015-07-21 | 2017-01-26 | Dyax Corp. | A monoclonal antibody inhibitor of factor xiia |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
AU2017247004B2 (en) * | 2016-04-06 | 2022-07-07 | Csl Limited | Method of treating atherosclerosis |
CN111479587B (en) | 2017-12-15 | 2024-01-09 | 杰特有限公司 | Use of FXIIIa inhibitors for the treatment of renal fibrosis and/or chronic kidney disease |
WO2019246176A1 (en) | 2018-06-19 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Anti-factor xii/xiia antibodies and uses thereof |
EP3886982A1 (en) * | 2018-11-28 | 2021-10-06 | Oregon Health & Science University | Therapeutic factor xii antibody |
KR20220058530A (en) | 2019-07-08 | 2022-05-09 | 레졸루트 인크 | Method for the preparation of plasma kallikrein inhibitors |
JP7088892B2 (en) | 2019-10-11 | 2022-06-21 | イビデン株式会社 | Insulation sheet for assembled battery and assembled battery |
US20230295343A1 (en) * | 2020-06-16 | 2023-09-21 | Ningbo Comgen Biotech Co., Ltd. | Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof |
AU2021401424A1 (en) | 2020-12-18 | 2023-06-29 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating factor xii |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK225488D0 (en) * | 1988-04-26 | 1988-04-26 | Novo Industri As | POLYPEPTIDE |
US4963657A (en) * | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
WO1994020535A1 (en) | 1992-12-11 | 1994-09-15 | Corvas International, Inc. | ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR |
EP0719334A1 (en) | 1993-09-14 | 1996-07-03 | Genentech, Inc. | Pharmaceutical compositions containing ecotin and homologs thereof |
ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
DE19725014A1 (en) * | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotinin variants with improved properties and bikunins of aprotinin variants |
GB9800817D0 (en) | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
US6403381B1 (en) * | 1998-06-08 | 2002-06-11 | University Of Vermont And State Agriculture College | Inhibition of coagulation in blood and blood products |
AU760735B2 (en) * | 1998-09-28 | 2003-05-22 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
ES2346189T3 (en) * | 2001-01-11 | 2010-10-13 | Life Sciences Research Partners Vzw | PHARMACEUTICAL METHOD AND COMPOSITION TO PREVENT AND / OR TREAT THE GENERALIZED INFLAMMATORY RESPONSE SYNDROME. |
US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
EP2298278B1 (en) * | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
WO2004004640A2 (en) | 2002-07-05 | 2004-01-15 | Tetragrammaton Inc. | Methods, compositions and kits for treating damage to excitable tissue |
ES2709103T3 (en) * | 2002-08-28 | 2019-04-15 | Dyax Corp | Methods to preserve organs and tissues |
US20040229778A1 (en) | 2003-05-13 | 2004-11-18 | Elmaleh David R. | Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases |
WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
US7544853B2 (en) | 2003-05-16 | 2009-06-09 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life transient treatment |
EP1673134A4 (en) | 2003-09-12 | 2007-03-21 | Marinepolymer Tech Inc | Vascular access preservation in hemodialysis patients |
GB0411145D0 (en) | 2004-05-19 | 2004-06-23 | Imp College Innovations Ltd | Protease inhibitors and their therapeutic applications |
US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
GB0418877D0 (en) | 2004-08-24 | 2004-09-29 | Univ Edinburgh | Heart |
US20060104944A1 (en) | 2004-11-18 | 2006-05-18 | Mousa Shaker A | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use |
ATE469650T1 (en) | 2004-12-01 | 2010-06-15 | Par Pharmaceuticals Inc | USE OF MEGESTROL ACETATE TO IMPROVE HEART FUNCTION AND TREAT HEART FAILURE |
-
2005
- 2005-12-20 BR BRPI0519349A patent/BRPI0519349A8/en not_active Application Discontinuation
- 2005-12-20 MX MX2007006997A patent/MX2007006997A/en active IP Right Grant
- 2005-12-20 JP JP2007547323A patent/JP5118492B2/en active Active
- 2005-12-20 PL PL05820601T patent/PL1830924T3/en unknown
- 2005-12-20 WO PCT/EP2005/013714 patent/WO2006066878A1/en active Application Filing
- 2005-12-20 EP EP05820601A patent/EP1830924B1/en active Active
- 2005-12-20 US US11/793,820 patent/US8119137B2/en active Active
- 2005-12-20 CA CA2591786A patent/CA2591786C/en active Active
- 2005-12-20 RU RU2007123797/14A patent/RU2514878C2/en not_active Application Discontinuation
- 2005-12-20 KR KR1020077016992A patent/KR101277097B1/en active IP Right Grant
- 2005-12-20 DK DK05820601.2T patent/DK1830924T3/en active
- 2005-12-20 AU AU2005318464A patent/AU2005318464B2/en active Active
- 2005-12-20 EP EP10183075A patent/EP2272565A3/en not_active Withdrawn
- 2005-12-20 CN CNA2005800465756A patent/CN101102819A/en active Pending
- 2005-12-20 ES ES05820601T patent/ES2407965T3/en active Active
-
2011
- 2011-12-29 US US13/339,793 patent/US20120148688A1/en not_active Abandoned
-
2012
- 2012-12-21 US US13/723,847 patent/US8715672B2/en active Active
Non-Patent Citations (9)
Title |
---|
AUBIN F ET AL: "Case report of aprotinin in Achilles tendinopathies with athletes", JOURNAL DE PHARMACIE CLINIQUE, vol. 16, no. 4, December 1997 (1997-12-01), pages 270 - 273, ISSN: 0291-1981 * |
CAPASSO G ET AL: "Preliminary results with peritendinous protease inhibitor injections in the management of Achilles tendinitis", JOURNAL OF SPORTS TRAUMATOLOGY AND RELATED RESEARCH, vol. 15, no. 1, 1993, pages 37 - 43, ISSN: 1120-3137 * |
CHU ARTHUR J ET AL: "Anticoagulant potential of an antibody against factor VII", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 114, no. 1, 1 September 2003 (2003-09-01), pages 37 - 41, XP002340056, ISSN: 0022-4804, DOI: 10.1016/S0022-4804(03)00277-4 * |
COLMAN ET AL: "Hemostasis and Thrombosis. Basic Principles and Clinical Practice", 1 January 2001, LIPPINCOTT, USA, ISBN: 0-7817-1455-9, article COLMAN: CHAPTER 6; BOCK: CHAPTER 16;, pages: 69 * |
EMEA, COMMITEE FOR MEDICINAL PRODUCTS FOR HUMAN USE: "Guide on production and quality control of monoclonal antibodies and related substances", 5 April 2007, EMEA, London, article EMEA/CHMP/BWP/157653/2007 * |
R. W. COLMAN: "Are hemostasis and thrombosis two sides of the same coin?", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 203, no. 3, 1 March 2006 (2006-03-01), pages 493 - 495, XP055000470, ISSN: 0022-1007, DOI: 10.1084/jem.20060217 * |
STASSEN J M ET AL: "Characterisation of a novel series of aprotinin-derived anticoagulants: II. Comparative antithrombotic effects on primary thrombus formation in vivo", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 74, no. 2, 1 January 1995 (1995-01-01), pages 655 - 659, XP008094685, ISSN: 0340-6245 * |
WILLIAMS ANTHONY ET AL: "DX-88 and HAE: a developmental perspective.", December 2003, TRANSFUSION AND APHERESIS SCIENCE : OFFICIAL JOURNAL OF THE WORLD APHERESIS ASSOCIATION : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR HAEMAPHERESIS DEC 2003, VOL. 29, NR. 3, PAGE(S) 255 - 258, ISSN: 1473-0502 * |
WILLIAMS ANTHONY ET AL: "DX-88 and HAE: a developmental perspective.", TRANSFUSION AND APHERESIS SCIENCE : OFFICIAL JOURNAL OF THE WORLD APHERESIS ASSOCIATION : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR HAEMAPHERESIS DEC 2003, vol. 29, no. 3, December 2003 (2003-12-01), pages 255 - 258, ISSN: 1473-0502 * |
Also Published As
Publication number | Publication date |
---|---|
US8119137B2 (en) | 2012-02-21 |
US8715672B2 (en) | 2014-05-06 |
KR101277097B1 (en) | 2013-06-20 |
CN101102819A (en) | 2008-01-09 |
EP1830924A1 (en) | 2007-09-12 |
US20130164301A1 (en) | 2013-06-27 |
KR20070092303A (en) | 2007-09-12 |
US20080254039A1 (en) | 2008-10-16 |
CA2591786A1 (en) | 2006-06-29 |
US20120148688A1 (en) | 2012-06-14 |
JP2008525342A (en) | 2008-07-17 |
RU2007123797A (en) | 2009-01-10 |
DK1830924T3 (en) | 2013-05-21 |
CA2591786C (en) | 2013-07-16 |
AU2005318464A1 (en) | 2006-06-29 |
EP2272565A3 (en) | 2012-03-28 |
WO2006066878A1 (en) | 2006-06-29 |
AU2005318464B2 (en) | 2012-02-23 |
PL1830924T3 (en) | 2013-08-30 |
EP2272565A2 (en) | 2011-01-12 |
JP5118492B2 (en) | 2013-01-16 |
BRPI0519349A2 (en) | 2009-01-20 |
MX2007006997A (en) | 2007-10-10 |
BRPI0519349A8 (en) | 2017-09-12 |
RU2514878C2 (en) | 2014-05-10 |
ES2407965T3 (en) | 2013-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1830924B1 (en) | Prevention of thrombus formation and/or stabilization | |
Westaby | Aprotinin in perspective | |
Esmon et al. | An update on clinical and basic aspects of the protein C anticoagulant pathway | |
Renné et al. | Defective thrombus formation in mice lacking coagulation factor XII | |
Renné et al. | In vivo roles of factor XII | |
Woodruff et al. | The many faces of the contact pathway and their role in thrombosis | |
CA2916399C (en) | Combination therapy using a factor xii inhibitor and a c1-inhibitor | |
Renné et al. | Factor XI deficiency in animal models | |
US9243044B2 (en) | Anticoagulant polypeptide and applications thereof | |
KR20020062698A (en) | Medicament for the protection against thrombotic diseases | |
Subramaniam et al. | Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP) | |
US20130071396A1 (en) | Method of inhibiting coagulation activation with human anti-factor v antibodies and use thereof | |
JP2009503009A (en) | Direct and indirect effector cell protease receptor-1 (EPR-1) inhibitors as antiplatelet agents | |
Boldt et al. | Continuous heparinization and circulating adhesion molecules in the critically ill | |
Hirsh et al. | C. Thrombogenesis | |
Kunitada et al. | Inhibitors of factor Xa | |
Esmon | Coagulation and Innate Immunity | |
Hagedorn | Novel mechanisms underlying arterial thrombus formation: in vivo studies in (genetically modified) mice | |
Factor | In vivo roles of factor XII | |
Westaby | Aprotinin Fifteen Years Later | |
de Jonge | Pathophysiology and management of coagulation disorders in critical care medicine | |
Shore-Lesserson et al. | CASE CONFERENCE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070723 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NIESWANDT, BERNHARD Inventor name: RENNE, THOMAS |
|
17Q | First examination report despatched |
Effective date: 20071108 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/36 20060101ALI20120831BHEP Ipc: A61K 38/56 20060101ALI20120831BHEP Ipc: A61P 7/02 20060101AFI20120831BHEP Ipc: A61K 39/395 20060101ALI20120831BHEP Ipc: C07K 16/40 20060101ALI20120831BHEP Ipc: C07K 14/81 20060101ALI20120831BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CSL BEHRING GMBH |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RENNE, THOMAS Inventor name: NIESWANDT, BERNHARD |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 598178 Country of ref document: AT Kind code of ref document: T Effective date: 20130315 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005038383 Country of ref document: DE Effective date: 20130425 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: FIAMMENGHI-FIAMMENGHI, CH |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2407965 Country of ref document: ES Kind code of ref document: T3 Effective date: 20130617 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130627 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130528 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130627 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20131128 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005038383 Country of ref document: DE Effective date: 20131128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20051220 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230428 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20230928 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231116 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231026 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20231010 Year of fee payment: 19 Ref country code: LU Payment date: 20231214 Year of fee payment: 19 Ref country code: IT Payment date: 20231110 Year of fee payment: 19 Ref country code: IE Payment date: 20231009 Year of fee payment: 19 Ref country code: FR Payment date: 20231108 Year of fee payment: 19 Ref country code: DK Payment date: 20231215 Year of fee payment: 19 Ref country code: DE Payment date: 20231024 Year of fee payment: 19 Ref country code: AT Payment date: 20231127 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20231121 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240116 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240101 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20231219 Year of fee payment: 19 |